DrugPatentWatch Database Preview
MAVYRET Drug Profile
Which patents cover Mavyret, and when can generic versions of Mavyret launch?
Mavyret is a drug marketed by Abbvie Inc and is included in one NDA. There are six patents protecting this drug.
The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.
Summary for MAVYRET
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 5 |
| Drug Prices: | Drug price information for MAVYRET |
| DailyMed Link: | MAVYRET at DailyMed |
Generic Entry Opportunity Date for MAVYRET
Generic Entry Date for MAVYRET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for MAVYRET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Abbvie Inc | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Abbvie Inc | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for MAVYRET
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2802180 | ➤ Try a Free Trial |
| Spain | 2560003 | ➤ Try a Free Trial |
| European Patent Office | 2853531 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for MAVYRET
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017000076 | Germany | ➤ Try a Free Trial | PRODUCT NAME: GLECAPREVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER ESTER DAVON; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 668 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119 |
| 2015012 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: OMBITASVIRUM; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
